Group 1 - The company has issued 12 million convertible bonds, known as "Aojia Convertible Bonds" (bond code: 128097), which were listed on March 18, 2020 [1][2] - The adjustment of the conversion price for the convertible bonds will occur based on specific corporate actions such as stock dividends, capital increases, and cash dividends [1][2] - The conversion price before adjustment is 9.45 CNY per share, and the adjusted conversion price will be 9.35 CNY per share, effective from May 29, 2025 [3] Group 2 - The company will distribute a cash dividend of 1.00 CNY (including tax) for every 10 shares based on the total share capital of 623,476,857 shares [2] - The conversion period for the "Aojia Convertible Bonds" is from September 2, 2020, to February 25, 2026 [3]

Core Points - The company has announced its profit distribution plan for the fiscal year 2024, which includes a cash dividend of RMB 1.00 for every 10 shares held, with no bonus shares or capital reserve conversion [1][2] - The total share capital of the company is 623,476,857 shares, and the cash dividend will be distributed based on this figure [2][3] - The record date for the distribution is set for May 28, 2025, and the ex-dividend date is May 29, 2025 [3] Profit Distribution Plan - The profit distribution plan specifies that shareholders will receive RMB 1.00 per 10 shares, with different tax treatments for various types of shareholders [2][3] - For Hong Kong market investors and certain foreign institutions, the cash dividend will be RMB 0.90 per 10 shares due to tax considerations [2] - The company will not withhold individual income tax at the time of distribution; instead, it will be calculated based on the holding period when shares are sold [3] Convertible Bond Adjustments - The company's convertible bonds, known as "Aojia Convertible Bonds," will have their conversion price adjusted from RMB 9.45 to RMB 9.35 per share following the profit distribution [3][4] - This adjustment will take effect on May 29, 2025, after the completion of the profit distribution [3]

| 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2025-22 | 号 | | --- | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | | 一、关于可转换公司债券转股价格调整的相关规定 奥佳华智能健康科技集团股份有限公司（以下简称"公司"或"本公司"） 公开发行了 1,200 万张可转换公司债券（债券简称：奥佳转债，债券代码：128097） 并于 2020 年 3 月 18 日上市。根据《公司公开发行可转换公司债券募集说明书》 及中国证券监督管理委员会（以下简称"中国证监会"）关于可转换公司债券发 行的有关规定，在本次可转换公司债券发行之后，当公司因派送股票股利、转增 股本、增发新股（不包括因本次可转换公司债券转股而增加的股本）、配股使公 司股份发生变化及派送现金股利等情况时，将按下述公式进行转股价格的调整 （保留小数点后两位，最后一位四舍五入）： 派送股票股利或转增股本：P1=P0/（1+n） 增发新股或配股：P1=（P0+A×k）/（1+k） 上述两项同时进行：P1=（P0+A×k）/（1+n+k） 奥佳华智能健康科技集团股份有限公司 关 ...

奥佳华智能健康科技集团股份有限公司 | 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2025-21 | 号 | | --- | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | | 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 奥佳华智能健康科技集团股份有限公司（以下简称"公司"或"本公司"） 2024 年年度权益分派方案已获 2025 年 5 月 20 日召开的 2024 年年度股东大会审 议通过，现将权益分派事宜公告如下： 一、股东大会审议通过利润分配方案的情况 1、公司 2024 年年度股东大会审议通过了《关于公司 2024 年度利润分配预 案的议案》，公司 2024 年度利润分配方案为：以公司未来实施 2024 年度权益分 配方案时股权登记日的总股本为基数，向全体股东每 10 股派发现金股利人民币 1.00 元（含税），预计派发现金股利人民币 62,347,675.20 元（含税），本年度 不送红股，不进行资本公积转增股本。若在利润分配预案公布后至实施前， ...

特此公告。 奥佳华智能健康科技集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 鉴于奥佳华智能健康科技集团股份有限公司（以下简称"公司"）将于近日 实施公司 2024 年度权益分派，根据《公司公开发行可转换公司债券募集说明书》 中"转股价格的调整方式及计算公式"条款的规定，自 2025 年 5 月 22 日起至本 次权益分派股权登记日止，公司可转换公司债券（债券简称：奥佳转债；债券代 码：128097）将暂停转股，本次权益分派股权登记日后的第一个交易日起恢复转 股。 在上述期间，公司可转换公司债券正常交易，敬请公司可转换公司债券持有 人注意。 | 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2025-20 | 号 | | --- | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | | 董 事 会 奥佳华智能健康科技集团股份有限公司 关于实施权益分派期间"奥佳转债"暂停转股的公告 2025 年 5 月 21 日 1、债券代码：128097，债券简称：奥佳转债 2、转股起止 ...

Summary of Key Points Core Viewpoint The announcement details the resolutions made during the 2024 Annual General Meeting of the company, highlighting the approval of various financial and operational reports, as well as the voting results from shareholders. Group 1: Meeting Details - The 2024 Annual General Meeting was held on May 20, 2025, at 14:30 in Xiamen, with both on-site and online voting options available [4][5][6]. - A total of 167 shareholders and their representatives attended, representing 252,535,641 shares, approximately 40.50% of the total shares [6][8]. - The meeting was chaired by the Vice Chairman due to the Chairman's absence [5]. Group 2: Voting Results - The financial resolution for the 2024 fiscal year was approved with 99.74% of votes in favor [9]. - The profit distribution proposal for 2024 received 99.74% approval [10]. - The board and supervisory reports for 2024 were also approved with similar high support, around 99.81% for the supervisory report [12][11]. - The 2025 financial budget proposal was approved with 97.53% in favor, but faced significant opposition from minority investors [15]. - The proposal for the appointment of the auditing firm for 2025 was approved with 99.83% support [16]. - A three-year shareholder return plan was approved with 99.82% in favor [17]. - The proposal to increase the guarantee limit for subsidiaries in 2025 was approved with 99.71% support [18]. Group 3: Legal Opinions - The legal opinion confirmed that the meeting's procedures, participant qualifications, and voting processes complied with relevant laws and regulations [20][39]. - The meeting's resolutions were deemed valid and legally binding [39].

| 股票简称：奥佳华 | 公告编号：2025-19 号 | | --- | --- | | 证券代码：002614 | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有出现否决议案的情形； 2、本次股东大会不涉及变更前次股东大会决议。 债券代码：128097 债券简称：奥佳转债 奥佳华智能健康科技集团股份有限公司 关于 2024 年年度股东大会决议的公告 一、会议召开和出席情况 奥佳华智能健康科技集团股份有限公司（以下简称"公司"）2024 年年度 股东大会（以下简称"本次股东大会"）通知于 2025 年 4 月 29 日在《中国证 券报》、《上海证券报》、《证券时报》、《证券日报》及巨潮资讯网（www.cninfo.com.cn） 上以公告方式发出。 （一）会议召开的情况 1、本次股东大会召开时间 （1）现场会议召开时间：2025 年 5 月 20 日（星期二）下午 14:30 （2）网络投票时间：2025 年 5 月 20 日，其中，通过深圳证券交易所系统进 行网络投票的时间为2025年5月20日9:15~9:25，9: ...

厦门·上海·福州·泉州·龙岩 http://www.tenetlaw.com 关于奥佳华智能健康科技集团股份有限公司 2024 年年度股东大会的 法律意见书 中国﹒厦门 厦禾路 666 号海翼大厦 A 幢 16-18 楼 中国﹒厦门 厦禾路 666 号海翼大厦 A 幢 16-18 楼 电话：86·592·5883666 传真：86·592·5881668 厦门·泉州·福州·龙岩·上海 www.tenetlaw.com 关于奥佳华智能健康科技集团股份有限公司 2024 年年度股东大会的 法律意见书 （2025）天衡（意）字第 111 号 致：奥佳华智能健康科技集团股份有限公司 奥佳华智能健康科技集团股份有限公司（以下简称"公司"）2024 年年度股 东大会（以下简称"本次股东大会"）于 2025 年 5 月 20 日召开。福建天衡联合 律师事务所（以下简称"本所"）接受公司的委托，指派荆日扬律师、廖明骐律 师（以下简称"本所律师"）出席本次股东大会，根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《上市公司股东会规则》（以下简称"《股东会 规则》"）和《奥佳华智能健康科技集团股份有限公司章程》（以下简 ...

Group 1: R&D and Innovation - The company emphasizes R&D investment in forward-looking technologies such as AI, automotive massage chairs, and medical rehabilitation robots, adjusting resource allocation based on technology maturity and market pace [2] - In 2024, the company launched the industry's first 5D flagship core, achieving advancements in core hardware and breakthroughs in AI algorithms and health management systems [2][3] Group 2: Financial Performance and Management - The company maintains a stable gross profit margin while focusing on cost reduction and efficiency improvements, despite facing rigid expenditure in brand building and R&D [3] - The management is committed to enhancing operational quality and international production layout to improve market competitiveness and resilience [3] Group 3: Market Position and Brand Development - The company has established multiple brands, including OGAWA and ihoco, which rank among the top three in their respective markets across Asia, North America, and Europe [3] - The company has maintained its industry leadership for 19 consecutive years, with products distributed in over 80 countries and regions [3]

Industry Overview - The massage chair industry combines traditional Chinese medicine techniques with modern technology, providing comfort and health benefits to users [1][4] - The market size of massage chairs in China is projected to grow from 6.191 billion yuan in 2019 to 8.485 billion yuan in 2024, indicating a robust development trend [1][10] - The sales volume of massage chairs is expected to increase from 1.2583 million units in 2019 to 1.5682 million units in 2024, reflecting a growing consumer demand [8][10] Market Environment - As of the end of 2024, the population aged 65 and above in China is projected to reach 220 million, accounting for 15.64% of the total population, driving demand for health-related products like massage chairs [6] - Over 70% of the population is in a sub-health state, with a significant portion being young adults, indicating a shift in the target demographic for massage chairs [6][8] - The increasing health awareness and changing consumption patterns among the middle class and young professionals are contributing to the stable growth of the massage chair market [8][10] Competitive Landscape - The massage chair market is characterized by intense competition between domestic and international brands, with leading domestic brands like OGAWA and Rongtai Health gaining market share [14][19] - The rise of e-commerce and shared economy models has led to the emergence of new players in the market, intensifying competition, especially in the mid-to-low-end segments [14][22] - The market is seeing a shift from traditional manufacturing to brand-driven strategies, enhancing brand value and consumer loyalty [14][19] Development Trends - The integration of smart technology and personalized services is becoming a key trend, with massage chairs utilizing AI and IoT to offer customized massage experiences [21][24] - The application scenarios for massage chairs are expanding beyond homes and offices to include public spaces like hotels and airports, enhancing consumer accessibility [22][23] - There is a growing trend towards integrating massage chairs with smart home systems, allowing for comprehensive health management solutions [24]